Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $9.1 million.

  • Stoke Therapeutics' Cash from Investing Activities rose 130.31% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$124.9 million, marking a year-over-year decrease of 33.58%. This contributed to the annual value of -$107.5 million for FY2024, which is 201.44% down from last year.
  • Stoke Therapeutics' Cash from Investing Activities amounted to $9.1 million in Q3 2025, which was up 106.12% from -$148.5 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Cash from Investing Activities high stood at $67.3 million for Q3 2022, and its period low was -$148.5 million during Q2 2025.
  • For the 3-year period, Stoke Therapeutics' Cash from Investing Activities averaged around -$11.6 million, with its median value being $10.0 million (2024).
  • In the last 5 years, Stoke Therapeutics' Cash from Investing Activities skyrocketed by 15,977.40% in 2023 and then plummeted by 476.08% in 2024.
  • Stoke Therapeutics' Cash from Investing Activities (Quarterly) stood at $22.5 million in 2022, then tumbled by 34.32% to $14.8 million in 2023, then slumped by 94.46% to $819,000 in 2024, then surged by 130.31% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, -$148.5 million for Q2 2025, and $13.6 million during Q1 2025.